QuotedData

Quoted Data

sign up for emailed equity research
Quick  |   Customised Register
Latest News
Home  »  Biotech and Healthcare News  »  Syncona remains at high premium and highly geared to Autolus

Syncona remains at high premium and highly geared to Autolus

10
2018
August

Syncona remains at high premium and highly geared to Autolus

Syncona’s shares have been the second best performer this year among the 14 biotech investment trusts monitored by Marten & Co, rising by 24.5% in the first seven months to end July. However, the trust’s NAV has only gained 8.7% in the period and thus its premium to NAV has grown to ~33%. Furthermore, the company’s 33% stake in Autolus Therapeutics (Nasdaq: AUTL), the recently floated second-generation CAR-T company, represents a relatively large – 35% –  share of its portfolio value, as well as 21.5% of NAV and more than 16% of its market capitalisation, according to calculations by Marten & Co.

Among developments in the second quarter, Syncona made a £9.8m commitment to a new (as yet undisclosed) portfolio company that uses a novel technology platform to enable the discovery of therapeutics acting at targets in the cell membrane. the company has also reported that in July, it sold its entire holding in Endocyte, realising a gain of £10.2m on an original investment of £4.0m.

Syncona’s investments, as of 30 June, are shown in the table below:

Investment  % Ownership Value 30/3  (£m) Value 30/6  (£m) % NAV
Autolus 33% 85.1 275.8 21.5%
Blue Earth Diagnostics 89% 186.8 213.2 16.6%
Nightstar Therapeutics 42% 124.5 147.9 11.5%
Freeline Therapeutics 80% 36 63.5 4.9%
CRT Pioneer Fund n/a 24.1 31.8 2.5%
Gyroscope Therapeutics 78% 11 11 0.9%
Orbit Biomedical 80% 8.6 9.1 0.7%
Achilles Therapeutics 69% 6.6 6.6 0.5%
SwanBio 72% 4.9 5.2 0.4%
“New portfolio company” 46% 0 3.5 0.3%
CEGX 9% 9.8 10.4 0.8%
Subtotal portfolio 514.5 789.4 61.5%
Total NAV (inc fund holdings) 1,055.8 1,283.2 100.0%

Contact us

captcha
Share This

Share This

Share this with your peers and friends!